Ad5-nCOV-S vaccine against COVID-19 manufactured by CanSino Biologicals is a non-replicative adenovirus vector-based vaccine that received WHO Emergency Use Listing (EUL) in May 2022. The WHO EUL process evaluates the quality of manufacturing along with safety and efficacy of the vaccine. All of the vaccines that have achieved WHO Emergency Use Listing can be considered safe and highly effective in preventing severe disease and hospitalization due to COVID-19.

As of 31 December 2021, about 58 million doses of Ad5-nCoV-S had been distributed worldwide. This vaccine is recommended for people aged 18 years and above.

Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations for use of COVID-19 vaccines:

https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials